References
- Banker MJ, Clark TH, Williams JA. (2003). Development and validation of 96-well equilibrium dialysis apparatus for measuring plasma protein binding. J Pharm Sci 92:967–974.
- Barnett A. (2006). DPP-4 inhibitors and their potential role in the management of type 2 diabetes. Int J Clin Pract 60:1454–1470.
- Deacon CF, Carr RD, Holst JJ. (2008). DPP-4 inhibitor therapy: new directions in the treatment of type 2 diabetes. Front Biosci 13:1780–1794.
- Fettman MJ, Allen TA, Wilke WL, Radin MJ, Eubank MC. (1985). Single-injection method for evaluation of renal function with14C-inulin and 3H-tetraethylammonium bromide in dogs and cats. Am J Vet Res 46:482–485.
- Gupta R, Walunj SS, Tokala RK, Parsa KVL, Singh SK, Pal M. (2009). Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of type 2 diabetes. Curr Drug Targets 10:71–87.
- Jin J-S, Zhao Y-F, Nakamura N, Akao T, Kakiuchi N, Hattori M. (2007). Isolation and characterization of a human intestinal bacterium, Eubacterium sp. ARC-2, capable of demethylating arctigenin, in the essential metabolic process to enterolactone. Biol Pharm Bull 30:904–911.
- Kern TS, Engerman RL. (1991). Renal hemodynamics in experimentally galactosemic dogs and diabetic dogs. Metabolism 40:450–454.
- Kompanowska-Jezierska E, Wolff H, Kuczeriszka M, Gramsbergen JB, Walkowska A, Johns EJ, Bie P. (2008). Renal nerves and nNOS: roles in natriuresis of acute isovolumetric sodium loading in conscious rats. Am J Physiol Regul Integr Comp Physiol 294:R1130–R1139.
- Krieter PA, Colletti AE, Doss GA, Miller RR. (1994). Disposition and metabolism of the hypoglycemic agent pioglitazone in rats. Drug Metab Disp 22:625–630.
- Mattei P, Boehringer M, Di Giorgio P, Fischer H, Hennig M, Huwyler J, Koçer B, Kuhn B, Loeffler BM, MacDonald A, Narquizian R, Rauber E, Sebokova E, Sprecher U. (2010). Discovery of carmegliptin: a potent and long-acting dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Bioorg Med Chem Lett 20:1109–1113.
- Omura T, Sato R. (1964). The carbon monoxide binding pigment of liver microsomes II solubilization, purification and properties. J Biol Chem 239:2379–2385.
- Schinkel AH, Wagenaar E, van Deemter L, Mol CAAM, Borst P. (1995). Absence of the mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporine A. J Clin Invest 96:1698–1705.
- Schwab D, Fischer H, Tabatabaei A, Poli S, Huwyler J. (2003). Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery. J Med Chem 46:1716–1725.
- Sebokova E, Christ AD, Boehringer M, Mizrahl J. (2007). Dipeptidyl peptidase IV inhibitors: the next generation of new promissing therapies for the management of type 2 diabetes. Curr Top Med Chem 7:547–555.
- Seglen PO. (1973). Preparation of rat liver cells. III. Enzymatic requirements for tissue dispersion. Exp Cell Res 82:391–398.
- Smith PK, Krohn RI, Hermanson G, Mallia AK, Gartner FH, Provenzano MD, Fujimoto EK, Goeke NM, Olson BJ, Klenk DC. (1985). Measurement of protein using bicinchoninic acid. Anal Biochem 150:76–85.
- Tahara H, Kusuhara H, Chida M, Fuse E, Sugiyama Y. (2006). Is the monkey an appropriate animal model to examine drug–drug interactions involving renal clearance? Effect of probenecid on the renal elimination of H2 receptor antagonists. J Pharmacol Exp Ther 316:1187–1194.
- Van der Hoeven TA, Coon MJ. (1974). Preparation and properties of partially purified cytochrome P-450 and reduced nicotinamide adenine dinucleotide phosphate-cytochrome P-450 reductase from rabbit liver microsomes. J Biol Chem 249:6302–6310.
- Wang L-Q, Meselhy MR, Li Y, Qin G-W, Hattori M. (2000). Human intestinal bacteria capable of transforming secoisolariciresinol diglucoside to mammalian lignans, enterodiol and enterolactone. Chem Parm Bull 48:1606–1610.